Covance Announces Exclusive Relationship with INphoton, LLC For Microscopy Imaging Services
|View printer-friendly version||<< Back|
—Covance increases its discovery and translational services imaging portfolio with high resolution intravital microscopy technology and expertise—
Princeton, NJ — Oct 12, 2010 — Covance and INphoton LLC today announced a collaborative relationship which will grant Covance exclusive global access to INphoton’s intravital microscopy imaging technology and expertise.
The new services offered as a result of the companies’ collaboration will include intravital microscopy and associated 3D image reconstruction and will offer clients:
• High resolution quantitative assays of the in vivo physiological effects of drugs;
• High resolution quantitative assays of in vivo drug distribution and pharmacokinetics;
• Characterization of the mechanisms and kinetics of renal and hepatic drug clearance; and
• Consultation on the feasibility, design and interpretation of imaging studies.
Dr. Michael A. Dorato, Vice President of Covance Discovery Services, stated, “The unique imaging capabilities of both organizations will allow our scientific teams to integrate intravital microscopy with Covance’s extensive molecular and anatomical imaging expertise focusing on specific client queries in the early discovery/development phase. The ultimate benefit is enabling our clients to make resource- and time-saving decisions on compounds earlier in the drug development process.”
Intravital microscopy is a technique that provides quantitative, in vivo molecular imaging at subcellular resolution, resulting in a cost-effective approach to accelerate preclinical drug development. State-of-the-art multiphoton microscopy combined with novel surgical techniques and multiple fluorophores allow in vivo imaging at subcellular resolution. These innovative high-content imaging technologies provide visibility of quantitative organ, cellular and subcellular distribution of potential therapeutic compounds as well as physiologic data, facilitating an understanding of efficacy and safety. Clients have found that the unique insights provided by in vivo multiphoton microscopy provide for more in-depth decision making data.
Steven Plump, CEO of INphoton LLC, commented, “Aligning our innovative high resolution imaging technology with Covance will provide customers an array of customized solutions to expedite drug development.”
INphoton provides customized imaging solutions using cutting-edge quantitative technologies in microscopy. We deliver cell-specific evaluation of drug distribution, efficacy and toxicity in vivo with unparalleled mechanistic insight. Our commitment is to our customers and helping expedite their drug candidates in the preclinical development process. For more information on INphoton, please visit our website at www.inphoton.com.
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide. Information on Covance’s products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company’s business are based largely on management’s expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company’s ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company’s filings with the Securities and Exchange Commission.
# # #